Thursday, 18 April 2024

[the_ad_group id="2845"]

Business News

Trinity Biotech targets annualized run-rate revenues of $75M by 2Q25 – TipRanks Financial Blog

Penumbra upgraded to Buy from Neutral at Citi

[the_ad id="21475"]


The Company is targeting approximately $20 million of Annualised Run-Rate EBITDASO on annualised run-rate revenues of approximately $75 million by Q2, 2025. This outlook is predicated solely on growth from the existing businesses including haemoglobin testing and HIV, and planned improvements to operating margins, with no contribution from the recently acquired biosensor business.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Click Here to Read the Full Original Article at TipRanks Financial Blog…


[the_ad id="21476"]